Cara Therapeutics (CARA) Bullish View Reiterated at Laidlaw Following Licence Agreement with Vifor Fresenius Medical
Tweet Send to a Friend
Laidlaw analyst Francois Brisebois reiterated a Buy rating and $26 price target on Cara Therapeutics (NASDAQ: CARA) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
